Springer CJ - Search Results

1

Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF.

Wan PT, Garnett MJ, Roe SM, Lee S, Niculescu-Duvaz D, Good VM, Jones CM, Marshall CJ, Springer CJ, Barford D, Marais R; Cancer Genome Project. Wan PT, et al. Among authors: springer cj. Cell. 2004 Mar 19;116(6):855-67. doi: 10.1016/s0092-8674(04)00215-6. Cell. 2004. PMID: 15035987 Free article.

2

Nilotinib and MEK inhibitors induce synthetic lethality through paradoxical activation of RAF in drug-resistant chronic myeloid leukemia.

Packer LM, Rana S, Hayward R, O'Hare T, Eide CA, Rebocho A, Heidorn S, Zabriskie MS, Niculescu-Duvaz I, Druker BJ, Springer C, Marais R. Packer LM, et al. Cancer Cell. 2011 Dec 13;20(6):715-27. doi: 10.1016/j.ccr.2011.11.004. Cancer Cell. 2011. PMID: 22169110 Free PMC article.

3

Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF.

Heidorn SJ, Milagre C, Whittaker S, Nourry A, Niculescu-Duvas I, Dhomen N, Hussain J, Reis-Filho JS, Springer CJ, Pritchard C, Marais R. Heidorn SJ, et al. Among authors: springer cj. Cell. 2010 Jan 22;140(2):209-21. doi: 10.1016/j.cell.2009.12.040. Cell. 2010. PMID: 20141835 Free PMC article.

4

B-RAF is a therapeutic target in melanoma.

Karasarides M, Chiloeches A, Hayward R, Niculescu-Duvaz D, Scanlon I, Friedlos F, Ogilvie L, Hedley D, Martin J, Marshall CJ, Springer CJ, Marais R. Karasarides M, et al. Among authors: springer cj. Oncogene. 2004 Aug 19;23(37):6292-8. doi: 10.1038/sj.onc.1207785. Oncogene. 2004. PMID: 15208680

5

Identification of inhibitors of the kinase activity of oncogenic V600E BRAF in an enzyme cascade high-throughput screen.

Newbatt Y, Burns S, Hayward R, Whittaker S, Kirk R, Marshall C, Springer C, McDonald E; Cancer Genome Project; Marais R, Workman P, Aherne W. Newbatt Y, et al. J Biomol Screen. 2006 Mar;11(2):145-54. doi: 10.1177/1087057105283584. Epub 2005 Dec 16. J Biomol Screen. 2006. PMID: 16361694

6

The EGF receptor Hokey-Cokey.

Niculescu-Duvaz D, Whittaker S, Springer C, Marais R. Niculescu-Duvaz D, et al. Cancer Cell. 2007 Mar;11(3):209-11. doi: 10.1016/j.ccr.2007.02.021. Cancer Cell. 2007. PMID: 17349577 Free article.

7

Gatekeeper mutations mediate resistance to BRAF-targeted therapies.

Whittaker S, Kirk R, Hayward R, Zambon A, Viros A, Cantarino N, Affolter A, Nourry A, Niculescu-Duvaz D, Springer C, Marais R. Whittaker S, et al. Sci Transl Med. 2010 Jun 9;2(35):35ra41. doi: 10.1126/scitranslmed.3000758. Sci Transl Med. 2010. PMID: 20538618

8

Paradox-breaking RAF inhibitors that also target SRC are effective in drug-resistant BRAF mutant melanoma.

Girotti MR, Lopes F, Preece N, Niculescu-Duvaz D, Zambon A, Davies L, Whittaker S, Saturno G, Viros A, Pedersen M, Suijkerbuijk BM, Menard D, McLeary R, Johnson L, Fish L, Ejiama S, Sanchez-Laorden B, Hohloch J, Carragher N, Macleod K, Ashton G, Marusiak AA, Fusi A, Brognard J, Frame M, Lorigan P, Marais R, Springer C. Girotti MR, et al. Cancer Cell. 2015 Jan 12;27(1):85-96. doi: 10.1016/j.ccell.2014.11.006. Epub 2014 Dec 11. Cancer Cell. 2015. PMID: 25500121 Free PMC article.

9

V599EB-RAF is an oncogene in melanocytes.

Wellbrock C, Ogilvie L, Hedley D, Karasarides M, Martin J, Niculescu-Duvaz D, Springer CJ, Marais R. Wellbrock C, et al. Among authors: springer cj. Cancer Res. 2004 Apr 1;64(7):2338-42. doi: 10.1158/0008-5472.can-03-3433. Cancer Res. 2004. PMID: 15059882

10

Serine and tyrosine phosphorylations cooperate in Raf-1, but not B-Raf activation.

Mason CS, Springer CJ, Cooper RG, Superti-Furga G, Marshall CJ, Marais R. Mason CS, et al. Among authors: springer cj. EMBO J. 1999 Apr 15;18(8):2137-48. doi: 10.1093/emboj/18.8.2137. EMBO J. 1999. PMID: 10205168 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

141 results

Search Page